je.st
news
Tag: bladder
Large scale epidemiological study associates PM2.5, NO2 pollution with kidney, bladder and colorectal cancer death
2017-10-31 20:55:38| Green Car Congress
Tags: large
study
death
associates
Mercks KEYTRUDA (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
2016-11-12 17:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancers (SITC) 31 st Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced bladder (urothelial) cancer previously treated with platinum-containing chemotherapy. As previously announced, KEYTRUDA was superior to investigator-choice chemotherapy for the primary endpoint of overall survival (OS) in this phase 3 study, and was stopped early. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
compared
previously
significantly
Mercks KEYNOTE-045 Studying KEYTRUDA (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
2016-10-21 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
early
primary
cancer
Lightweight Bladder Tanks Fueling The UAV Industry
2016-03-03 11:31:10| Industrial Newsroom - All News for Today
Aero Tec Laboratories (ATL) of Ramsey, New Jersey, an AS 9100C registered company, manufactures extremely lightweight yet ultra rugged flexible fuel bladder tanks for the unmanned aerospace industry. Many industry leaders such as AAI/Textron, Boeing, General Atomics and Raytheon, depend on ATLs bladder tanks to...
Tags: industry
tanks
lightweight
bladder
Bladder Control at Waterblasting Technologies
2015-12-04 11:39:00| Airport Technology
Waterblasting Technologies are constantly thinking of ways to make our machines better and more efficient. This has led to the bladder, one of our newest innovations.
Tags: control
technologies
bladder
waterblasting